Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication

Shintaro Ban, Youki Ueda, Masao Ohashi, Kenji Matsuno, Masanori Ikeda, Nobuyuki Kato, Hiroyuki Miyachi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

It has been reported that ligand-mediated transcription factor peroxisome proliferator-activated receptor alpha (hPPARα) is involved in hepatitis C virus (HCV) RNA replication, whereas hPPARγ is not, and the effect of hPPARδ is unknown. Here, we show that hPPARδ-selective antagonists effectively inhibit HCV RNA replication. We describe the design, synthesis and pharmacological evaluation of a series of biphenyl-4-carboxylic acid-type hPPARδ antagonists, including previously reported compounds, as candidate anti-HCV agents. A representative compound (4c) dose-dependently inhibited HCV RNA replication (EC50 0.22 μM), while exhibiting relatively weak cytotoxicity to the host cells (CC50 2.5 μM). It also showed an additive and dose-dependent effect on the inhibition of HCV RNA replication by pegylated interferon alpha (Peg-IFNα) alone and by both Peg-IFNα and ribavirin (currently the clinical treatment of choice for HCV infection). Thus, combination of a hPPARδ antagonist with current therapy may improve the efficacy of treatment for HCV infection.

Original languageEnglish
Pages (from-to)4774-4778
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume23
Issue number17
DOIs
Publication statusPublished - Sep 1 2013

Fingerprint

PPAR delta
Virus Replication
Viruses
Hepacivirus
RNA
Virus Diseases
Interferon-alpha
PPAR alpha
Ribavirin
Cytotoxicity
Carboxylic Acids
Transcription Factors
Pharmacology
Ligands

Keywords

  • Biphenyl-4-carboxylic acid
  • HCV RNA replication
  • PPAR delta
  • PPAR delta antagonist

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication. / Ban, Shintaro; Ueda, Youki; Ohashi, Masao; Matsuno, Kenji; Ikeda, Masanori; Kato, Nobuyuki; Miyachi, Hiroyuki.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 23, No. 17, 01.09.2013, p. 4774-4778.

Research output: Contribution to journalArticle

Ban, Shintaro ; Ueda, Youki ; Ohashi, Masao ; Matsuno, Kenji ; Ikeda, Masanori ; Kato, Nobuyuki ; Miyachi, Hiroyuki. / Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication. In: Bioorganic and Medicinal Chemistry Letters. 2013 ; Vol. 23, No. 17. pp. 4774-4778.
@article{e003460b3ce741db8ba88508a0fb0531,
title = "Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication",
abstract = "It has been reported that ligand-mediated transcription factor peroxisome proliferator-activated receptor alpha (hPPARα) is involved in hepatitis C virus (HCV) RNA replication, whereas hPPARγ is not, and the effect of hPPARδ is unknown. Here, we show that hPPARδ-selective antagonists effectively inhibit HCV RNA replication. We describe the design, synthesis and pharmacological evaluation of a series of biphenyl-4-carboxylic acid-type hPPARδ antagonists, including previously reported compounds, as candidate anti-HCV agents. A representative compound (4c) dose-dependently inhibited HCV RNA replication (EC50 0.22 μM), while exhibiting relatively weak cytotoxicity to the host cells (CC50 2.5 μM). It also showed an additive and dose-dependent effect on the inhibition of HCV RNA replication by pegylated interferon alpha (Peg-IFNα) alone and by both Peg-IFNα and ribavirin (currently the clinical treatment of choice for HCV infection). Thus, combination of a hPPARδ antagonist with current therapy may improve the efficacy of treatment for HCV infection.",
keywords = "Biphenyl-4-carboxylic acid, HCV RNA replication, PPAR delta, PPAR delta antagonist",
author = "Shintaro Ban and Youki Ueda and Masao Ohashi and Kenji Matsuno and Masanori Ikeda and Nobuyuki Kato and Hiroyuki Miyachi",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.bmcl.2013.07.005",
language = "English",
volume = "23",
pages = "4774--4778",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "17",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication

AU - Ban, Shintaro

AU - Ueda, Youki

AU - Ohashi, Masao

AU - Matsuno, Kenji

AU - Ikeda, Masanori

AU - Kato, Nobuyuki

AU - Miyachi, Hiroyuki

PY - 2013/9/1

Y1 - 2013/9/1

N2 - It has been reported that ligand-mediated transcription factor peroxisome proliferator-activated receptor alpha (hPPARα) is involved in hepatitis C virus (HCV) RNA replication, whereas hPPARγ is not, and the effect of hPPARδ is unknown. Here, we show that hPPARδ-selective antagonists effectively inhibit HCV RNA replication. We describe the design, synthesis and pharmacological evaluation of a series of biphenyl-4-carboxylic acid-type hPPARδ antagonists, including previously reported compounds, as candidate anti-HCV agents. A representative compound (4c) dose-dependently inhibited HCV RNA replication (EC50 0.22 μM), while exhibiting relatively weak cytotoxicity to the host cells (CC50 2.5 μM). It also showed an additive and dose-dependent effect on the inhibition of HCV RNA replication by pegylated interferon alpha (Peg-IFNα) alone and by both Peg-IFNα and ribavirin (currently the clinical treatment of choice for HCV infection). Thus, combination of a hPPARδ antagonist with current therapy may improve the efficacy of treatment for HCV infection.

AB - It has been reported that ligand-mediated transcription factor peroxisome proliferator-activated receptor alpha (hPPARα) is involved in hepatitis C virus (HCV) RNA replication, whereas hPPARγ is not, and the effect of hPPARδ is unknown. Here, we show that hPPARδ-selective antagonists effectively inhibit HCV RNA replication. We describe the design, synthesis and pharmacological evaluation of a series of biphenyl-4-carboxylic acid-type hPPARδ antagonists, including previously reported compounds, as candidate anti-HCV agents. A representative compound (4c) dose-dependently inhibited HCV RNA replication (EC50 0.22 μM), while exhibiting relatively weak cytotoxicity to the host cells (CC50 2.5 μM). It also showed an additive and dose-dependent effect on the inhibition of HCV RNA replication by pegylated interferon alpha (Peg-IFNα) alone and by both Peg-IFNα and ribavirin (currently the clinical treatment of choice for HCV infection). Thus, combination of a hPPARδ antagonist with current therapy may improve the efficacy of treatment for HCV infection.

KW - Biphenyl-4-carboxylic acid

KW - HCV RNA replication

KW - PPAR delta

KW - PPAR delta antagonist

UR - http://www.scopus.com/inward/record.url?scp=84881372652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881372652&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2013.07.005

DO - 10.1016/j.bmcl.2013.07.005

M3 - Article

C2 - 23891183

AN - SCOPUS:84881372652

VL - 23

SP - 4774

EP - 4778

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 17

ER -